PDF icon PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · Sleep Sci 2022; 15(01): 128-135
DOI: 10.5935/1984-0063.20220032
REVIEWS

The hypothalamic-pituitary-adrenal axis and the central monoaminergic systems: a pathophysiological link to insomnia with clinical implications

Marcio Luciano de Souza Bezerra 
1   RioSono Sleep Center, Sleep Medicine - Rio de Janeiro - RJ - Brazil.
,
Raimundo Nonato Delgado Rodrigues
2   Unidade do Sono de Brasilia DF, Sleep Medicine - Brasilia - DF - Brazil.
,
Ricardo Oliveira Souza
3   Instituto de Pesquisa da Rede D’Or, Neurology - Rio de Janeiro - RJ - Brazil.
› Institutsangaben
› Weitere Informationen
Auch verfügbar aufeRef
  Lizenzen und Reprints
Preview

ABSTRACT

The authors present a theoretical overview of the hypothalamic-pituitary-adrenal axis and the central monoaminergic systems, focusing on a putative pathophysiological relationship to insomnia complaints. Insomnia is an independent and self-perpetuating disorder that requires diagnostic and therapeutic attention in the presence of concomitant disorders, likely with bidirectional influence. An adequate understanding of such mechanisms can help for a better understanding of the interplay between clinical features, neurotransmitters, and the adrenal hypothalamic-pituitary axis may help clinicians to better manage insomnia patients

Keywords:

Autonomic Nervous System - Hypothalamic Hormones - Adrenal Cortex Hormones - Sleep - Sleep Deprivation


Publikationsverlauf

Eingereicht: 02. April 2021

Angenommen: 09. Juli 2021

Artikel online veröffentlicht:
01. Dezember 2023

© 2022. Brazilian Sleep Association. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • REFERENCES

  • 1 Vgontzas AN, Bixler EO, Lin HM, Prolo P, Mastorakos G, Vela-Bueno A, et al. Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: Clinical implications. J Clin Endocrinol Metab. 2001 Aug;86(8):3787-94.
  • 2 Leech JA. Changes in sleep duration and recreational screen time among Canadians, 1998-2010. J Sleep Res. 2017;26(2):202-9.
  • 3 Maslansky R. A review of “insomnia: a cultural history.” J Addict Dis. 2011 Mar;30(2):181-2.
  • 4 Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. Chest. 2014 Nov;146(5):1387-94.
  • 5 Diagn M, Mentais SDET. O manual diagnóstico e estatístico de transtornos mentais e a psicose. Rev Psicol Cienc Afines. 2013;10:26-32.
  • 6 Spielman AJ, Caruso LS, Glovinsky PB. A behavioral perspective on insomnia treatment. Psychiatr Clin North Am. 1987 Dec;10(4):541-53.
  • 7 Menon JML, Nolten C, Achterberg EJM, Joosten RNJMA, Dematteis M, Feenstra MGP, et al. Brain microdialysate monoamines in relation to circadian rhythms, sleep, and sleep deprivation - a systematic review, network meta-analysis, and new primary data. J Circadian Rhythms. 2019;17(1):1-32.
  • 8 Born J, Kern W, Bieber K, Fehm-Wolfsdorf G, Schiebe M, Fehm HL. Night-time plasma cortisol secretion is associated with specific sleep stages. Biol Psychiatry. 1986 Dec;21(14):1415-24.
  • 9 Weibel L, Follenius M, Spiegel K, Ehrhart J, Brandenberger G. Comparative effect of night and daytime sleep on the 24-hour cortisol secretory profile. Sleep. 1995 Sep;18(7):549-56.
  • 10 Rodenbeck GH, Hajak G. Neuroendocrine dysregulation in primary insomnia. Rev Neurol 2001 Nov;157(11 Pt 2)S57-61.
  • 11 Baglioni C, Battagliese G, Feige B, Spiegelhalder K, Nissen C, Voderholzer U, et al. Insomnia as a predictor of depression: A meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord. 2011 Dec;135(1-3):10-9.
  • 12 Li M, Zhang XW, Hou WS, Tang ZY. Insomnia and risk of cardiovascular disease: a meta-analysis of cohort studies. Int J Cardiol. 2014 Oct;176(3):104-7.
  • 13 Meng L, Zheng Y, Hui R. The relationship of sleep duration and insomnia to risk of hypertension incidence: a meta-analysis of prospective cohort studies. Hypertens Res. 2013 Nov;36(11):985-95.
  • 14 Anothaisintawee T, Reutrakul S, Van Cauter E, Thakkinstian A. Sleep disturbances compared to traditional risk factors for diabetes development: systematic review and meta-analysis. Sleep Med Rev. 2016 Dec;30:11-24.
  • 15 Fortier-Brochu É, Beaulieu-Bonneau S, Ivers H, Morin CM. Insomnia and daytime cognitive performance: a meta-analysis. Sleep Med Rev. 2012 Feb;16(1):83-94.
  • 16 Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011 Sep;21(9):655-79.
  • 17 Eftekhari S, Edvinsson L. Possible sites of action of the new calcitonin gene-related peptide receptor antagonists. Ther Adv Neurol Disord. 2010 Nov;3(6):369-78.
  • 18 Kim SJ, Han KT, Jang SY, Yoo KB, Kim SJ. The association between migraine and types of sleep disorder. Int J Environ Res Public Health. 2018 Dec;15(12):2648.
  • 19 Lin YK, Lin GY, Lee JT, Lee MS, Tsai CK, Hsu YW, et al. Associations between sleep quality and migraine frequency. Medicine (Baltimore). 2016 Apr;95(17):e3554.
  • 20 Houle TT, Butschek RA, Turner DP, Smitherman TA, Rains JC, Penzien DB. Stress and sleep duration predict headache severity in chronic headache sufferers. Pain. 2012 Dec;153(12):2432-40.
  • 21 Bigal ME, Hargreaves RJ. Why does sleep stop migraine? Curr Pain Headache Rep. 2013 Oct;17(10):369.
  • 22 Aggarwal M, Puri V, Puri S. Serotonin and CGRP in migraine. Ann Neurosci. 2012 Apr;19(2):88-94.
  • 23 Comings DE. Serotonin: a key to migraine disorders? Nutr Heal Rev. 1994;.
  • 24 Miglis MG. Migraine and autonomic dysfunction: which is the horse and which is the jockey? Curr Pain Headache Rep. 2018;22(3):19.
  • 25 Patacchioli FR, Monnazzi P, Simeoni S, De Filippis S, Salvatori E, Coloprisco G, et al. Salivary cortisol, dehydroepiandrosterone-sulphate (DHEA-S) and testosterone in women with chronic migraine. J Headache Pain. 2006 Apr;7(2):90-4.
  • 26 Gadermann AM, Engel CC, Naifeh JAP, Nock MK, Petukhova M, Santiago PN, et al. Prevalence of DSM-IV major depression among U.S. military personnel: meta-analysis and simulation. Mil Med. 2012 Aug;177(Suppl 8):47-59.
  • 27 Fernandez-Mendoza J, Shea AS, Vgontzas N, Calhoun SL, Bixler EO. Insomnia and incident depression: role of objective sleep duration and natural history. J Sleep Res. 2015 Aug;24(4):390-8.
  • 28 Albert PR, Benkelfat C, Descarries L. The neurobiology of depression-revisiting the serotonin hypothesis. I. cellular and molecular mechanisms. Philos Trans R Soc B Biol Sci. 2012 Sep;367(1601):2378-81.
  • 29 Andrews PW, Bharwani A, Lee KR, Fox M, Thomson Junior JA. Is serotonin an upper or a downer? The evolution of the serotonergic system and its role in depression and the antidepressant response. Neurosci Biobehav Rev. 2015 Apr;51:164-88.
  • 30 Murri MB, Pariante C, Mondelli V, Masotti M, Atti AR, Mellacqua Z, et al. HPA axis and aging in depression: systematic review and meta-analysis. Psychoneuroendocrinology. 2014 Mar;41:46-62.
  • 31 Stetler C, Miller GE. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom Med. 2011 Feb/Mar;73(2):114-26.
  • 32 Singla S, Jhamb S, Singh AK. Depression affects autonomic system of the body? Yes, it does! J Educ Health Promot. 2020;9(31):1-7.
  • 33 Bellato A, Arora I, Hollis C, Groom MJ. Is autonomic nervous system function atypical in attention deficit hyperactivity disorder (ADHD)? A systematic review of the evidence. Neurosci Biobehav Rev. 2020;108:182-206.
  • 34 Wynchank D, Bijlenga D, Beekman AT, Kooij JJS, Penninx BW. Adult attention-deficit/hyperactivity disorder (ADHD) and insomnia: an update of the literature. Curr Psychiatry Rep. 2017;19(12):98.
  • 35 Brevik EJ, Lundervold AJ, Halmøy A, Posserud MB, Instanes JT, Bjorvatn B, et al. Prevalence and clinical correlates of insomnia in adults with attention-deficit hyperactivity disorder. Acta Psychiatr Scand. 2017 Aug;136(2):220-7.
  • 36 Bush G. Attention-deficit/hyperactivity disorder and attention networks. Neuropsychopharmacology. 2010;35(1):278-300.
  • 37 Banerjee E, Nandagopal K. Does serotonin deficit mediate susceptibility to ADHD? Neurochem Int. 2015 Mar;82:52-68.
  • 38 Isaksson J, Nilsson KW, Nyberg F, Hogmark Å, Lindblad F. Cortisol levels in children with attention-deficit/hyperactivity disorder. J Psychiatr Res. 2012 Nov;46(11):1398-405.
  • 39 Videnovic A. Management of sleep disorders in Parkinson’s disease and multiple system atrophy. Mov Disord. 2017 May;32(5):659-68.
  • 40 Ratti PL, Nègre-Pagès L, Pérez-Lloret S, Manni R, Damier P, Tison F, et al. Subjective sleep dysfunction and insomnia symptoms in Parkinson’s disease: Insights from a cross-sectional evaluation of the French CoPark cohort. Parkinsonism Relat Disord. 2015 Nov;21(11):1323-9.
  • 41 Schrempf W, Brandt MD, Storch A, Reichmann H. Sleep disorders in Parkinson’s disease. J Parkinsons Dis. 2014;4(2):211-21.
  • 42 Ongini E, Caporali MG, Massotti M. Stimulation of dopamine D-1 receptors by SKF 38393 induces EEG desynchronization and behavioral arousal. Life Sci. 1985 DEc;37(24):2327-33.
  • 43 Rye DB. Parkinson’s disease and RLS: the dopaminergic bridge. Sleep Med. 2004 May;5(3):317-28.
  • 44 Chen Z, Li G, Liu J. Autonomic dysfunction in Parkinson’s disease: implications for pathophysiology, diagnosis, and treatment. Neurobiol Dis. 2020 Feb;134:104700.
  • 45 Bellomo G, Santambrogio L, Fiacconi M, Scarponi AM, Ciuffetti G. Plasma profiles of adrenocorticotropic hormone, cortisol, growth hormone and prolactin in patients with untreated Parkinson’s disease. J Neurol. 1991 Feb;238(1):19-22.
  • 46 Cote TE, Felder R, Kebabian JW, Sekura RD, Reisine T, Affolter HU. D-2 dopamine receptor-mediated inhibition of pro-opiomelanocortin synthesis in rat intermediate lobe. Abolition by pertussis toxin or activators of adenylate cyclase. J Biol Chem. 1986 Apr;261(10):4555-61.
  • 47 Bezerra MLS, Martínez JVL. Zolpidem in restless legs syndrome. Eur Neurol. 2002;48(3):180-1.
  • 48 Allen RP, Bharmal M, Calloway M. Prevalence and disease burden of primary restless legs syndrome: results of a general population survey in the United States. Mov Disord. 2011 Jan;26(1):114-20.
  • 49 Mohri I, Kato-Nishimura K, Tachibana N, Ozono K, Taniike M. Restless legs syndrome (RLS): an unrecognized cause for bedtime problems and insomnia in children. Sleep Med. 2008 Aug;9(6):701-2.
  • 50 Kushida C, Martin M, Nikam P, Blaisdell B, Wallenstein G, Ferini-Strambi L, et al. Burden of restless legs syndrome on health-related quality of life. Qual Life Res. 2007 May;16(4):617-24.
  • 51 Galbiati A, Marelli S, Giora E, Zucconi M, Oldani A, Ferini-Strambi L. Neurocognitive function in patients with idiopathic restless legs syndrome before and after treatment with dopamine-agonist. Int J Psychophysiol. 2015 Mar;95(3):304-9.
  • 52 Holstege JC, Dijken HVAN, Buijs RM, Goedknegt H, Gosens T. Distribution of dopamine immunoreactivity in the rat, and monkey spinal cord. Brain Res. 1996;376(4):631-52.
  • 53 Ondo WG, He Y, Rajasekaran S, Le WD. Clinical correlates of 6-hydroxydopamine injections into all dopaminergic neurons in rats: a possible model for restless legs syndrome? Mov Disord. 2000 Jan;15(1):154-8.
  • 54 Schilling C, Schredl M, Strobl P, Deuschle M. Restless legs syndrome: evidence for nocturnal hypothalamic-pituitary-adrenal system activation. Mov Disord. 2010 Jun;25(8):1047-52.
  • 55 Lattova Z, Keckeis M, Maurovich-Horvat E, Wetter TC, Wilde-Frenz J, Schuld A, et al. The stress hormone system in various sleep disorders. J Psychiatr Res. 2011 Nov/Dec;45(9):1223-8.
  • 56 Izzi F, Placidi F, Romigi A, Lauretti B, Marfia GA, Mercuri NB, et al. Is autonomic nervous system involved in restless legs syndrome during wakefulness? Sleep Med. 2014 Nov;15(11):1392-7.
  • 57 Taylor-Clark T. Histamine in allergic rhinitis. Adv Exp Med Biol. 2010;709:33-41.
  • 58 Buske-Kirschbaum A, Ebrecht M, Hellhammer DH. Blunted HPA axis responsiveness to stress in atopic patients is associated with the acuity and severeness of allergic inflammation. Brain Behav Immun. 2010 Nov;24(8):1347-53.
  • 59 Ishman SL, Martin TJ, Hambrook DW, Smith TL, Jaradeh SS, Loehrl TA. Autonomic nervous system evaluation in allergic rhinitis. Otolaryngol Head Neck Surg. 2007 Jan;136(1):51-6.
  • 60 Leger D, Bonnefoy B, Pigearias B, Giclais B, Chartier A. Poor sleep is highly associated with house dust mite allergic rhinitis in adults and children. Allergy Asthma Clin Immunol. 2017;13(1):1-9.
  • 61 Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020 Aug;396(10247):345-60.
  • 62 Lin TK, Zhong L, Santiago JL. Association between stress and the HPA axis in the atopic dermatitis. Int J Mol Sci. 2017;18(10):1-15.
  • 63 Slominski A, Wortsman J, Tuckey RC, Paus R. Differential expression of HPA axis homolog in the skin. Mol Cell Endocrinol. 2007;265-266:143-9.
  • 64 Mostaghimi L, Hetzel S. Insomnia and other sleep complaints in inflammatory versus noninflammatory skin disorders: an observational case-control study. Int J Dermatol. 2019 Aug;58(8):976-81.
  • 65 Fishbein AB, Mueller K, Kruse L, Boor P, Sheldon S, Zee P, et al. Sleep disturbance in children with moderate/severe atopic dermatitis: a case-control study. J Am Acad Dermatol. 2018;78(2):336-41.
  • 66 Maenner MJ, Shaw KA, Baio J, Washington A, Patrick M, Di Rienzo M, et al. Prevalence of autism spectrum disorder among children aged 8 years-autism and developmental disabilities monitoring network, 11 Sites, United States, 2016. MMWR Surveill Summ. 2020 Apr;69(4):1-12.
  • 67 Lake CR, Ziegler MG, Murphy DL. Increased norepinephrine levels and decreased dopamine-β-hydroxylase activity in primary autism. Arch Gen Psychiatry. 1977 May;34(5):553-6.
  • 68 Buckley AW, Hirtz D, Oskoui M, Armstrong MJ, Batra A, Bridgemohan C, et al. Practice guideline: treatment for insomnia and disrupted sleep behavior in children and adolescents with autism spectrum disorder: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2020 Mar;94(9):392-404.
  • 69 Richdale AL, Prior MR. Urinary cortisol circadian rhythm in a group of high-functioning children with autism. J Autism Dev Disord. 1992 Sep;22(3):433-47.
  • 70 Corbett BA, Mendoza S, Wegelin JA, Carmean V, Levine S. Variable cortisol circadian rhythms in children with autism and anticipatory stress. J Psychiatry Neurosci. 2008 May;33(3):227-34.
  • 71 Baker EK, Richdale AL, Hazi A, Prendergast LA. Assessing a hyperarousal hypothesis of insomnia in adults with autism spectrum disorder. Autism Res. 2019 Jun;12(6):897-910.
  • 72 Kushki A, Brian J, Dupuis A, Anagnostou E. Functional autonomic nervous system profile in children with autism spectrum disorder. Mol Autism. 2014;5(1):39.
  • 73 Benevides TW, Lane SJ. A review of cardiac autonomic measures: considerations for examination of physiological response in children with autism spectrum disorder. J Autism Dev Disord. 2013 Feb;45(2):560-75.
  • 74 Grandner MA, Alfonso-Miller P, Fernandez-Mendoza J, Shetty S, Shenoy S, Combs D. Sleep: important considerations for the prevention of cardiovascular disease. Curr Opin Cardiol. 2016 Sep;31(5):551-65.
  • 75 Floam S, Simpson N, Nemeth E, Scott-Sutherland J, Gautam S, Haack M. Sleep characteristics as predictor variables of stress systems markers in insomnia disorder. J Sleep Res. 2015 Jun;24(3):296-304.
  • 76 Gottlieb DJ, Redline S, Nieto FJ, Baldwin CM, Newman AB, Resnick HE, et al. Association of usual sleep duration with hypertension: the Sleep Heart Health Study. Sleep. 2006 Aug;29(8):1009-14.
  • 77 Amagai Y, Ishikawa S, Gotoh T, Doi Y, Kayaba K, Nakamura Y, et al. Sleep duration and mortality in Japan. J Epidemiol. 2004 Jul;14(4):124-8.
  • 78 Chandola T, Ferrie JE, Perski A, Akbaraly T, Marmot MG. The effect of short sleep duration on coronary heart disease risk is greatest among those with sleep disturbance: a prospective study from the Whitehall II cohort. Sleep. 2010 Jun;33(6):739-44.
  • 79 Leppävuori A, Pohjasvaara T, Vataja R, Kaste M, Erkinjuntti T. Insomnia in ischemic stroke patients. Cerebrovasc Dis. 2002;14(2):90-7.
  • 80 Leng Y, Cappuccio FP, Wainwright NWJ, Surtees PG, Luben R, Brayne C, et al. Sleep duration and risk of fatal and nonfatal stroke: a prospective study and meta-analysis. Neurology. 2015 Mar;84(11):1072-9.
  • 81 Helbig AK, Stöckl D, Heier M, Ladwig KH, Meisinger C. Symptoms of insomnia and sleep duration and their association with incident strokes: findings from the population-based MONICA/KORA Augsburg Cohort Study. PLoS One. 2015;10(7):e0134480.
  • 82 Barugh AJ, Gray P, Shenkin SD, MacLullich AMJ, Mead GE. Cortisol levels and the severity and outcomes of acute stroke: a systematic review. J Neurol. 2014 Mar;261(3):533-45.
  • 83 Inoue Y, Qin B, Poti J, Sokol R, Gordon-Larsen P. Epidemiology of obesity in adults: latest trends. Curr Obes Rep. 2018 Dec;7(4):276-88.
  • 84 Lucassen EA, Cizza G. The hypothalamic-pituitary-adrenal axis, obesity, and chronic stress exposure: sleep and the HPA Axis in Obesity. Curr Obes Rep. 2012 Dec;1(4):208-15.
  • 85 Pasquali R, Cantobelli S, Casimirri F, Capelli M, Bortoluzzi L, Flamia R, et al. The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution. J Clin Endocrinol Metab. 1993 Aug;77(2):341-6.
  • 86 Rasmussen MH, Wildschiødtz G, Juul A, Hilsted J. Polysomnographic sleep, growth hormone insulin-like growth factor-I axis, leptin, and weight loss. Obesity. 2008 Jul;16(7):1516-21.
  • 87 Guarino D, Nannipieri M, Iervasi G, Taddei S, Bruno RM. The role of the autonomic nervous system in the pathophysiology of obesity. Front Physiol. 2017;8:665.
  • 88 Landsberg L. Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why). J Hypertens. 2001 Mar;19(3 Suppl 1):523-8.
  • 89 Nixon JP, Mavanji V, Butterick TA, Billington CJ, Kotz CM, Teske JA. Sleep disorders, obesity, and aging: the role of orexin. Ageing Res Rev. 2015 Mar;20:63-73.
  • 90 Flügge G, Van Kampen M, Mijnster MJ. Perturbations in brain monoamine systems during stress. Cell Tissue Res. 2004 Feb;315(1):1-14.
  • 91 Dunlavey CJ. Introduction to the hypothalamic-pituitary-adrenal axis: healthy and dysregulated stress responses, developmental stress and neurodegeneration. J Undergrad Neurosci Educ. 2018 Jun;16(2):R59-60.